{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:03:09Z","timestamp":1794276189661,"version":"4.9.0"},"reference-count":94,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","award":["Vera Down grant (2013) & Margaret Temple (2017)"],"award-info":[{"award-number":["Vera Down grant (2013) & Margaret Temple (2017)"]}],"id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104079\/Z\/14\/Z"],"award-info":[{"award-number":["104079\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000295","name":"Epilepsy Research UK","doi-asserted-by":"publisher","award":["P1201"],"award-info":[{"award-number":["P1201"]}],"id":[{"id":"10.13039\/501100000295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V007173\/1"],"award-info":[{"award-number":["MR\/V007173\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2021,7,15]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour. Classically, well-characterised \u2018onconeuronal\u2019 antibodies target intracellular antigens and hence cannot access their antigens across intact cell membranes. The pathogenic mediators are likely to be neuronal-specific T cells. There is a variable response to immunotherapies and the clinical syndrome helps to direct the search for a specific set of tumours. By contrast, many newly emerging autoantibodies with oncological associations target cell surface epitopes and can exert direct pathogenic effects on both the central and peripheral nervous systems. Patients with these cell-surface directed autoantibodies often clearly respond to immunotherapies. Overall, the clinical, serological and oncological features in an individual patient help to determine the clinical relevance of the syndrome and hence guide its management. We summarise current knowledge and a practical approach to the investigation, diagnosis, treatment and outcomes of patients with suspected PNS.<\/jats:p>","DOI":"10.1136\/practneurol-2021-003073","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T13:20:35Z","timestamp":1631366435000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":103,"title":["Paraneoplastic neurological syndromes: a practical approach to diagnosis and management"],"prefix":"10.1136","volume":"22","author":[{"given":"Sophie","family":"Binks","sequence":"first","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Uy","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK"},{"name":"Department of Medicine (Division of Neurology), University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-5952","authenticated-orcid":false,"given":"Jerome","family":"Honnorat","sequence":"additional","affiliation":[{"name":"French Reference Centre on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hopital Neurologique, Lyon, France"},{"name":"SynatAc Team, Institute NeuroMyoGene INSERM U1217\/CNRS UMR 5310, Universite de Lyon, Universit Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-9748","authenticated-orcid":false,"given":"Sarosh R","family":"Irani","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK"},{"name":"Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2025090410261612000_22.1.19.1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00415-019-09544-1","article-title":"Epidemiology of paraneoplastic neurological syndromes: a population-based study","volume":"267","author":"Vogrig","year":"2020","journal-title":"J Neurol"},{"key":"2025090410261612000_22.1.19.2","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000883","article-title":"Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France","volume":"7","author":"H\u00e9bert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090410261612000_22.1.19.3","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2009.341","article-title":"Paraneoplastic neurologic syndrome in the PNS Euronetwork database","volume":"67","author":"Giometto","year":"2010","journal-title":"Arch Neurol"},{"key":"2025090410261612000_22.1.19.4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014"},{"key":"2025090410261612000_22.1.19.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.034447"},{"key":"2025090410261612000_22.1.19.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.10.1931"},{"key":"2025090410261612000_22.1.19.7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S2215-0366(19)30001-X","article-title":"The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data","volume":"6","author":"Al-Diwani","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2025090410261612000_22.1.19.8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamaneurol.2015.1715","article-title":"Clinical spectrum of encephalitis associated with antibodies against the \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature","volume":"72","author":"Joubert","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025090410261612000_22.1.19.9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/brain\/awz094","article-title":"The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies","volume":"142","author":"van Coevorden-Hameete","year":"2019","journal-title":"Brain"},{"key":"2025090410261612000_22.1.19.10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00415-019-09590-9","article-title":"The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis","volume":"268","author":"Ramanathan","year":"2021","journal-title":"J Neurol"},{"key":"2025090410261612000_22.1.19.11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2025090410261612000_22.1.19.12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2017.04.046","article-title":"Autoantibody-mediated diseases of the CNS: structure, dysfunction and therapy","volume":"132","author":"Varley","year":"2018","journal-title":"Neuropharmacology"},{"key":"2025090410261612000_22.1.19.13","doi-asserted-by":"crossref","DOI":"10.1136\/practneurol-2020-002567","article-title":"Autoimmune encephalitis: clinical spectrum and management","author":"Uy","year":"2021","journal-title":"Pract Neurol"},{"key":"2025090410261612000_22.1.19.14","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2017-001742"},{"key":"2025090410261612000_22.1.19.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323055"},{"key":"2025090410261612000_22.1.19.16","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090410261612000_22.1.19.17","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-1"},{"key":"2025090410261612000_22.1.19.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.10.1873"},{"key":"2025090410261612000_22.1.19.19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1288"},{"key":"2025090410261612000_22.1.19.20","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23550"},{"key":"2025090410261612000_22.1.19.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270515"},{"key":"2025090410261612000_22.1.19.22","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000113749.77217.01"},{"key":"2025090410261612000_22.1.19.23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","article-title":"Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"88","author":"Maddison","year":"2017","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.6.1138"},{"key":"2025090410261612000_22.1.19.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906103402303"},{"key":"2025090410261612000_22.1.19.26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-017-1802-y","article-title":"Genetic alterations and tumor immune attack in YO paraneoplastic cerebellar degeneration","volume":"135","author":"Small","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2025090410261612000_22.1.19.27","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0524-9"},{"key":"2025090410261612000_22.1.19.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1146"},{"key":"2025090410261612000_22.1.19.29","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I","article-title":"Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer","volume":"75","author":"Dalmau","year":"1995","journal-title":"Cancer"},{"key":"2025090410261612000_22.1.19.30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2010.05.035","article-title":"HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes","volume":"226","author":"de Graaf","year":"2010","journal-title":"J Neuroimmunol"},{"key":"2025090410261612000_22.1.19.31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2017.12.012","article-title":"Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies","volume":"315","author":"Hillary","year":"2018","journal-title":"J Neuroimmunol"},{"key":"2025090410261612000_22.1.19.32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.25173","article-title":"N-Methyl-D-Aspartate receptor antibody production from germinal center reactions: therapeutic implications","volume":"83","author":"Makuch","year":"2018","journal-title":"Ann Neurol"},{"key":"2025090410261612000_22.1.19.33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01022"},{"key":"2025090410261612000_22.1.19.34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"D\u00e9chelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090410261612000_22.1.19.35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1017\/cjn.2018.74","article-title":"The positive predictive value of Onconeural antibody testing: a retrospective review","volume":"45","author":"Budhram","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"2025090410261612000_22.1.19.36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2015.11.009","article-title":"Pitfalls in the detection of CV2 (CRMP5) antibodies","volume":"290","author":"Sabater","year":"2016","journal-title":"J Neuroimmunol"},{"key":"2025090410261612000_22.1.19.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816721"},{"key":"2025090410261612000_22.1.19.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2025090410261612000_22.1.19.39","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf006"},{"key":"2025090410261612000_22.1.19.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318296e9c3"},{"key":"2025090410261612000_22.1.19.41","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23577"},{"key":"2025090410261612000_22.1.19.42","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh203"},{"key":"2025090410261612000_22.1.19.43","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaneurol.2020.2231","article-title":"Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like protein-11 encephalitis","volume":"77","author":"Dubey","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025090410261612000_22.1.19.44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000666","article-title":"Clinical significance of Kelch-like protein 11 antibodies","volume":"7","author":"Maudes","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090410261612000_22.1.19.45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318584"},{"key":"2025090410261612000_22.1.19.46","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq113"},{"key":"2025090410261612000_22.1.19.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"2025090410261612000_22.1.19.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70224-2"},{"key":"2025090410261612000_22.1.19.49","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1212\/WNL.0000000000005614","article-title":"Encephalitis with mGluR5 antibodies: symptoms and antibody effects","volume":"90","author":"Spatola","year":"2018","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.5.713"},{"key":"2025090410261612000_22.1.19.51","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000041495.87539.98"},{"key":"2025090410261612000_22.1.19.52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000699","article-title":"Clinical spectrum and diagnostic pitfalls of neurologic syndromes with RI antibodies","volume":"7","author":"Simard","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090410261612000_22.1.19.53","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.2.225"},{"key":"2025090410261612000_22.1.19.54","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316829"},{"key":"2025090410261612000_22.1.19.55","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.118588"},{"key":"2025090410261612000_22.1.19.56","unstructured":"Suero GO , Escudero D , Saiz A . Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes, 2018."},{"key":"2025090410261612000_22.1.19.57","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.138016"},{"key":"2025090410261612000_22.1.19.58","doi-asserted-by":"crossref","first-page":"e3012","DOI":"10.1212\/WNL.0000000000010854","article-title":"Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.59","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/120.8.1279","article-title":"Small-Cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome","volume":"120 (Pt 8","author":"Mason","year":"1997","journal-title":"Brain"},{"key":"2025090410261612000_22.1.19.60","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410290303"},{"key":"2025090410261612000_22.1.19.61","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.209"},{"key":"2025090410261612000_22.1.19.62","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20529"},{"key":"2025090410261612000_22.1.19.63","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E"},{"key":"2025090410261612000_22.1.19.64","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx189"},{"key":"2025090410261612000_22.1.19.65","doi-asserted-by":"crossref","first-page":"E1873","DOI":"10.1212\/WNL.0000000000008472","article-title":"Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.66","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","article-title":"Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases","volume":"90","author":"Dubey","year":"2018","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.67","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archneurol.2011.128","article-title":"Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond","volume":"68","author":"McKeon","year":"2011","journal-title":"Arch Neurol"},{"key":"2025090410261612000_22.1.19.68","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000037485.56217.5F"},{"key":"2025090410261612000_22.1.19.69","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281663.81079.24"},{"key":"2025090410261612000_22.1.19.70","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1212\/WNL.0000000000011218","article-title":"Paraneoplastic myeloneuropathies","volume":"96","author":"Shah","year":"2021","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-537506"},{"key":"2025090410261612000_22.1.19.72","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d62eb"},{"key":"2025090410261612000_22.1.19.73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01266.x"},{"key":"2025090410261612000_22.1.19.74","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200109000-00004"},{"key":"2025090410261612000_22.1.19.75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-4-5","article-title":"Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy","volume":"4","author":"Adamus","year":"2004","journal-title":"BMC Ophthalmol"},{"key":"2025090410261612000_22.1.19.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.01.010"},{"key":"2025090410261612000_22.1.19.77","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9585f"},{"key":"2025090410261612000_22.1.19.78","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","article-title":"Characterization of a subtype of autoimmune encephalitis with anti-Contactin-Associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures","volume":"73","author":"Joubert","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025090410261612000_22.1.19.79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00415-018-9132-0","article-title":"Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis","volume":"266","author":"Maureille","year":"2019","journal-title":"J Neurol"},{"key":"2025090410261612000_22.1.19.80","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10178"},{"key":"2025090410261612000_22.1.19.81","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.0000000000003713","article-title":"Investigations in GABAA receptor antibody-associated encephalitis","volume":"88","author":"Spatola","year":"2017","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.82","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2017-001845"},{"key":"2025090410261612000_22.1.19.83","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182698cd8"},{"key":"2025090410261612000_22.1.19.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.04.006"},{"key":"2025090410261612000_22.1.19.85","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323226"},{"key":"2025090410261612000_22.1.19.86","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0706-4"},{"key":"2025090410261612000_22.1.19.87","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327342.58936.e0"},{"key":"2025090410261612000_22.1.19.88","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.4.479"},{"key":"2025090410261612000_22.1.19.89","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316904"},{"key":"2025090410261612000_22.1.19.90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-020-01788-z","article-title":"Rhombencephalitis associated with isolated Zic4-antibodies in paraneoplastic cerebellar degeneration: a case report","volume":"20","author":"Loehrer","year":"2020","journal-title":"BMC Neurol"},{"key":"2025090410261612000_22.1.19.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.09.001"},{"key":"2025090410261612000_22.1.19.92","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21315"},{"key":"2025090410261612000_22.1.19.93","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.59.5.764","article-title":"P\/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer","volume":"59","author":"Graus","year":"2002","journal-title":"Neurology"},{"key":"2025090410261612000_22.1.19.94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6169"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2021-003073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:26:30Z","timestamp":1757006790000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2021-003073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,20]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/practneurol-2021-003073"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2021-003073","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,11]]}}}